SCHEMBL3384664

SCHEMBL3384664

COC(=O)C(C(=O)OC)c1ncnc2c1ccn2S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
ALOX5 P09917 4/20 0.36
POLB P06746 1/20 0.35
ALDH3A1 P30838 1/20 0.35
HTT P42858 1/20 0.35
NOD1 Q9Y239 1/20 0.35
ACVR1 Q04771 1/20 0.35
BRD4 O60885 1/20 0.34
PTPN11 Q06124 1/20 0.34
ALDH1A1 P00352 3/20 0.34
RAPGEF4 Q8WZA2 1/20 0.34
MMP2 P08253 1/20 0.34
ANPEP P15144 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HCRTR1 O43613 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24262374 0.92 L3MBTL1 (0.43) L3MBTL1POLBALDH3A1HTTNOD1
SCHEMBL29080525 0.87 L3MBTL1 (0.46) L3MBTL1ALOX5POLBALDH3A1HTT
SCHEMBL3384671 0.87 L3MBTL1 (0.41) L3MBTL1ALOX5POLBPTPN11ALDH1A1
SCHEMBL6726762 0.78 L3MBTL1 (0.44) L3MBTL1ALOX5POLBALDH3A1HTT
SCHEMBL5411086 0.77 L3MBTL1 (0.50) L3MBTL1POLBALDH3A1HTTNOD1
SCHEMBL260617 0.77 L3MBTL1 (0.55) L3MBTL1POLBALDH3A1HTTNOD1
SCHEMBL13769391 0.76 L3MBTL1 (0.46) L3MBTL1NOD1ALDH1A1RAPGEF4KDM4E
SCHEMBL4068111 0.76 L3MBTL1 (0.49) L3MBTL1POLBALDH3A1HTTNOD1
SCHEMBL3556162 0.76 L3MBTL1 (0.49) L3MBTL1POLBALDH3A1HTTNOD1
SCHEMBL3391209 0.75 L3MBTL1 (0.50) L3MBTL1POLBALDH3A1HTTNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183248-B2 Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors IRM LLC (BM) 2012-05-22 US disclosed
US-8183248-B2 Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors IRM LLC (BM) 2012-05-22 US disclosed
EP-1891066-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-22 EP disclosed
US-20090118273-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2009-05-07 US disclosed
US-20090118273-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118273-A1 Compounds and Compositions as Protein Kinase Inhibitors SRC, FYN, SYK L3MBTL1 4367/4885ALOX5 4309/4885POLB 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.